<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473368</url>
  </required_header>
  <id_info>
    <org_study_id>2011P000389</org_study_id>
    <nct_id>NCT01473368</nct_id>
  </id_info>
  <brief_title>Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota</brief_title>
  <official_title>Open Label, Randomized Pilot Study to Examine The Effects of the Probiotic Saccharomyces Boulardii, the Antibiotic Amoxicillin/Clavulanate and the Combination on the Gut Microbiota of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocodex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and contrast the effects of the probiotic
      Saccharomyces boulardii, the antibiotic amoxicillin/clavulanate and the combination on the
      gut microbiota of healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>Day 0</time_frame>
    <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>Day 7</time_frame>
    <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal Symptoms Response Score</measure>
    <time_frame>Day 14</time_frame>
    <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal Symptoms Response Scale</measure>
    <time_frame>Day 21</time_frame>
    <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of Escherichia in Stool</measure>
    <time_frame>Day -7 to Day 21</time_frame>
    <description>Control arm was not assessed as there was no intervention for this group.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Operational Taxonomic Units</measure>
    <time_frame>Day 0 to Day 21</time_frame>
    <description>Core Microbiome includes control samples and baseline samples (Day -7 and Day 0) for antibiotic, probiotic, and combination groups. Data for Core microbiome for individual arms are not available.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>prebiotic (Saccharomyces boulardii)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg, 2 times daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antibiotic (Amoxicillin Clavulanate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination (prebiotic and antibiotic)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>500 mg, 2 times daily for 14 days</description>
    <arm_group_label>prebiotic (Saccharomyces boulardii)</arm_group_label>
    <arm_group_label>combination (prebiotic and antibiotic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Clavulanate</intervention_name>
    <description>875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
    <arm_group_label>antibiotic (Amoxicillin Clavulanate)</arm_group_label>
    <arm_group_label>combination (prebiotic and antibiotic)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years (male or female)

          -  Good general health

          -  Able to comply with study requirements and to provide informed consent

          -  For women of childbearing potential oA negative urine pregnancy test immediately prior
             to starting the study treatment oAgreement to comply with approved methods of
             contraception during the period of active study treatment (not required during
             follow-up)

        Exclusion Criteria:

          -  History of organ transplantation

          -  Known chronic or recurrent systemic disorder associated with immunocompromise

          -  A history of allergy or hypersensitivity to Saccharomyces boulardii, brewer's or
             baker's yeast, amoxicillin, penicillins, or cephalosporins

          -  History of severe allergic reaction (requiring hospital admission and/or the
             administration of parenteral medication or associated with dyspnoea, wheezing,
             hypotension, loss of consciousness).

          -  Oral or systemic antibacterial therapy during the 3 months prior to study enrollment

          -  New prescription medications during the 4 weeks prior to study enrollment

          -  Prescription, OTC medications or supplements that are known to alter gut function or
             microflora (i.e. acid antisecretory drugs, probiotics) during the 4 weeks prior to
             study enrollment

          -  Active gastrointestinal disease

          -  Patients with a central venous catheter

          -  Patients taking antifungals or laxatives within 14 days of enrolment

          -  Patients enrolled in other clinical trials within the past 60 days

          -  Prior gastrointestinal surgery (apart from appendectomy or cholecystectomy)

          -  History of chronic constipation with passage of fewer than 3 bowel movements per week
             on average

          -  Any condition or personal circumstance that, in the opinion of the investigator,
             renders the subject unlikely or unable to comply with the full study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciaran P Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <results_first_submitted>March 30, 2016</results_first_submitted>
  <results_first_submitted_qc>September 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 9, 2016</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Ciaran Kelly</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>human Gut Microbiota</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>gut microbiome</keyword>
  <keyword>probiotic</keyword>
  <keyword>antibiotic</keyword>
  <keyword>antibiotic-associated diarrhea</keyword>
  <keyword>intestinal bacterial overgrowth</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prebiotic (Saccharomyces Boulardii)</title>
          <description>Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
        </group>
        <group group_id="P2">
          <title>Antibiotic (Amoxicillin Clavulanate)</title>
          <description>Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
        </group>
        <group group_id="P3">
          <title>Combination (Prebiotic and Antibiotic)</title>
          <description>Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
        </group>
        <group group_id="P4">
          <title>Control</title>
          <description>Control group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prebiotic (Saccharomyces Boulardii)</title>
          <description>Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
        </group>
        <group group_id="B2">
          <title>Antibiotic (Amoxicillin Clavulanate)</title>
          <description>Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Combination (Prebiotic and Antibiotic)</title>
          <description>Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
        </group>
        <group group_id="B4">
          <title>Control</title>
          <description>control group</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="9.9"/>
                    <measurement group_id="B2" value="27.4" spread="6.6"/>
                    <measurement group_id="B3" value="34.2" spread="11.4"/>
                    <measurement group_id="B4" value="27.2" spread="4.3"/>
                    <measurement group_id="B5" value="30.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gastrointestinal Symptom Rating Scale</title>
        <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
        <time_frame>Day 0</time_frame>
        <population>Control participants were not assessed at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Prebiotic (Saccharomyces Boulardii)</title>
            <description>Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic (Amoxicillin Clavulanate)</title>
            <description>Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Combination (Prebiotic and Antibiotic)</title>
            <description>Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Symptom Rating Scale</title>
          <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
          <population>Control participants were not assessed at this time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" spread="5.4"/>
                    <measurement group_id="O2" value="18.7" spread="3.8"/>
                    <measurement group_id="O3" value="17.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gastrointestinal Symptom Rating Scale</title>
        <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prebiotic (Saccharomyces Boulardii)</title>
            <description>Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic (Amoxicillin Clavulanate)</title>
            <description>Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Combination (Prebiotic and Antibiotic)</title>
            <description>Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Symptom Rating Scale</title>
          <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="8.8"/>
                    <measurement group_id="O2" value="26.9" spread="14.2"/>
                    <measurement group_id="O3" value="18.1" spread="3.0"/>
                    <measurement group_id="O4" value="19.3" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gastrointestinal Symptoms Response Score</title>
        <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
        <time_frame>Day 14</time_frame>
        <population>Participants analyzed were those with complete data at Day 14</population>
        <group_list>
          <group group_id="O1">
            <title>Prebiotic (Saccharomyces Boulardii)</title>
            <description>Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic (Amoxicillin Clavulanate)</title>
            <description>Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Combination (Prebiotic and Antibiotic)</title>
            <description>Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Symptoms Response Score</title>
          <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
          <population>Participants analyzed were those with complete data at Day 14</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="5.1"/>
                    <measurement group_id="O2" value="20.3" spread="5.9"/>
                    <measurement group_id="O3" value="16.8" spread="1.6"/>
                    <measurement group_id="O4" value="18.1" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Gastrointestinal Symptoms Response Scale</title>
        <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
        <time_frame>Day 21</time_frame>
        <population>Participants analyzed were those with complete data at Day 14</population>
        <group_list>
          <group group_id="O1">
            <title>Prebiotic (Saccharomyces Boulardii)</title>
            <description>Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic (Amoxicillin Clavulanate)</title>
            <description>Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Combination (Prebiotic and Antibiotic)</title>
            <description>Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
          <group group_id="O4">
            <title>Control</title>
            <description>Control group</description>
          </group>
        </group_list>
        <measure>
          <title>Gastrointestinal Symptoms Response Scale</title>
          <description>Mean Gastrointestinal Symptom Rating Scale scores Range from 15 to 90 Increasing score means increasing symptoms</description>
          <population>Participants analyzed were those with complete data at Day 14</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="5.7"/>
                    <measurement group_id="O2" value="18.4" spread="5.8"/>
                    <measurement group_id="O3" value="16.5" spread="2.9"/>
                    <measurement group_id="O4" value="15.8" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Escherichia in Stool</title>
        <description>Control arm was not assessed as there was no intervention for this group.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
        <time_frame>Day -7 to Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prebiotic (Saccharomyces Boulardii) Before Treatment</title>
            <description>Before treatment
Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
          <group group_id="O2">
            <title>Prebiotic (Saccharomyces Boulardii) During Treatment</title>
            <description>During treatment
Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
          <group group_id="O3">
            <title>Prebiotic (Saccharomyces Boulardii) After Treatment</title>
            <description>After treatment
Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Escherichia in Stool</title>
          <description>Control arm was not assessed as there was no intervention for this group.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
          <units>percentage of total bacteria</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="0.0" spread="0"/>
                    <measurement group_id="O3" value="0.1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Escherichia in Stool</title>
        <description>Control arm was not assessed as there was no intervention for this group.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
        <time_frame>Day -7 to Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antibiotic (Amoxicillin Clavulanate) Before Treatment</title>
            <description>Before treatment
Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Antibiotic (Amoxicillin Clavulanate) During Treatment</title>
            <description>During treatment
Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
          <group group_id="O3">
            <title>Antibiotic (Amoxicillin Clavulanate) After Treatment</title>
            <description>After treatment
Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Escherichia in Stool</title>
          <description>Control arm was not assessed as there was no intervention for this group.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
          <units>percentage of total bacteria</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0"/>
                    <measurement group_id="O2" value="4.5" spread="0"/>
                    <measurement group_id="O3" value="0.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Escherichia in Stool</title>
        <description>Control arm was not assessed as there was no intervention for this group.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
        <time_frame>Day -7 to Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination (Prebiotic and Antibiotic) Before Treatment</title>
            <description>Before treatment
Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
          <group group_id="O2">
            <title>Combination (Prebiotic and Antibiotic) During Treatment</title>
            <description>During treatment
Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
          <group group_id="O3">
            <title>Combination (Prebiotic and Antibiotic) After Treatment</title>
            <description>After treatment
Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Escherichia in Stool</title>
          <description>Control arm was not assessed as there was no intervention for this group.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
          <units>percentage of total bacteria</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0"/>
                    <measurement group_id="O2" value="2.9" spread="0"/>
                    <measurement group_id="O3" value="0.2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Operational Taxonomic Units</title>
        <description>Core Microbiome includes control samples and baseline samples (Day -7 and Day 0) for antibiotic, probiotic, and combination groups. Data for Core microbiome for individual arms are not available.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
        <time_frame>Day 0 to Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination (Prebiotic and Antibiotic) During Treatment</title>
            <description>During Treatment
Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
          <group group_id="O2">
            <title>Combination (Prebiotic and Antibiotic) After Treatment</title>
            <description>After Treatment
Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
          </group>
          <group group_id="O3">
            <title>Antibiotic (Amoxicillin Clavulanate) During Treatment</title>
            <description>During Treatment
Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
          <group group_id="O4">
            <title>Antibiotic (Amoxicillin Clavulanate) After Treatment</title>
            <description>After Treatment
Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
          </group>
          <group group_id="O5">
            <title>Core Microbiome</title>
            <description>Core Microbiome</description>
          </group>
          <group group_id="O6">
            <title>Prebiotic (Saccharomyces Boulardii) During Treatment</title>
            <description>During Treatment
Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
          <group group_id="O7">
            <title>Prebiotic (Saccharomyces Boulardii) After Treatment</title>
            <description>After Treatment
Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Operational Taxonomic Units</title>
          <description>Core Microbiome includes control samples and baseline samples (Day -7 and Day 0) for antibiotic, probiotic, and combination groups. Data for Core microbiome for individual arms are not available.
Before Treatment: Average of Day -7 and Day 0 During Treatment: Average of Day 3, Day 7, Day 10, Day 13 After Treatment: Average of Day 21</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="49"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449.8" spread="210.1"/>
                    <measurement group_id="O2" value="509.9" spread="251.9"/>
                    <measurement group_id="O3" value="461.1" spread="228.2"/>
                    <measurement group_id="O4" value="668.8" spread="188.4"/>
                    <measurement group_id="O5" value="730.9" spread="240.4"/>
                    <measurement group_id="O6" value="776.7" spread="167.6"/>
                    <measurement group_id="O7" value="776.7" spread="749.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prebiotic (Saccharomyces Boulardii)</title>
          <description>Saccharomyces boulardii: 500 mg, 2 times daily for 14 days</description>
        </group>
        <group group_id="E2">
          <title>Antibiotic (Amoxicillin Clavulanate)</title>
          <description>Amoxicillin Clavulanate: 875/125 mg 2 times daily at least 1 hour before meals for 7 days</description>
        </group>
        <group group_id="E3">
          <title>Combination (Prebiotic and Antibiotic)</title>
          <description>Saccharomyces boulardii AND Amoxicillin Clavulanate: Amoxicillin Clavulanate for 7 days (days 1 to 7; 875/125 mg 2 times daily at least 1 hour before meals) in addition to the dietary supplement Saccharomyces boulardii for 14 days (days 1 to 14; 500 mg, 2 times daily).</description>
        </group>
        <group group_id="E4">
          <title>Control</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>eructation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>infrequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>regurgitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vulvovaginal rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ciaran Kelly, MD</name_or_title>
      <organization>Beth Israel Deacones Medical Center</organization>
      <phone>617-667-1272</phone>
      <email>ckelly2@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

